Oqory, Inc.
- Biotech or pharma, therapeutic R&D
Oqory is a clinical stage ADC company with a lead TROP2 ADC known as OQY-3258 that has been studied in China in over 150 patients with three subtypes of breast cancer: 1L and 3L TNBC and 2/3L HR+/HER2- breast cancer. We have an open IND in the US. We have an entire suite of ADC technologies, including antibody discovery and validation, and chemistries for linkers and payloads (topoisomerase 1 and MMAE/MMAF).
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}